[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline 20 August 2021]
We are inviting expressions of interest (EoI) for commercializing “Microbial Markers for Autism” technology. The innovation is developed by Professor Siew Chien Ng, Professor of the Department of Medicine and Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 20/MED/1004).
The Technology
Autism spectrum disorder (ASD) is a complex group of developmental disorders characterized by impaired social interactions and communication together with repetitive behaviors. The purpose of this invention is to determine bacterial biomarkers for people with autism, as well as to pinpoint probiotic/therapeutic bacteria for autism. The gut bacterial profile is different between autism children and typically developing children. Gut microbiota is regarded as an important factor in the development of ASD. The practical use of the invention includes predicting risk for autism in children and microbial transfer and/or supplementation is a potential route to improve behavioral symptom in autism patients.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
